Treatment of P. aeruginosa against Antimicrobial agents

Pseudomonas aeruginosa is one of the leading causes of nosocomial infections, reported world-wide. The gram negative, rod shaped bacterium is ubiquitous with normal nutritional requirement. P. aeruginosa is commonly encountered in health-associated infections. According to CDC, incidence of P. aeruginosa infections in U.S. hospitals averages about 0.4 % and the bacterium is the fourth most commonly isolated nosocomial pathogen accounting for 10.1% of all hospital acquired infections. Despite advances in sanitation facilities and the introduction of wide variety of antimicrobial agents with antipseudomonal activities of P. aeruginosa continue to be cause of life-threatening infections. With growing concerns about the development of biocidal resistance and cross-resistance with antibiotics, clinical isolates should be under continual surveillance and other possible mechanisms of resistance should be investigated. Also, antiseptic and disinfectant products can varies significantly in their activity despite containing similar levels of biocides, which underlies the need for close inspection of efficacy claims.